 HAMILTON, ON and BOSTON, May 6, 2021 PRNewswire -- Fusion Pharmaceuticals Inc. Nasdaq: FUSN, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck known as MSD outside the U.S. and Canada to evaluate Fusions lead candidate, 225Ac-FPI-1434 FPI-1434, in combination with Mercks anti-PD-1 programmed death receptor-1 therapy, KEYTRUDA pembrolizumab, in patients with solid tumors expressing insulin-like growth factor 1 receptor IGF-1R. With our strong preclinical data demonstrating promising activity with FPI-1434 and immuno-oncology agents, we believe we have an opportunity to improve efficacy in tumor indications where KEYTRUDA is approved, and to potentially expand into new tumor indications, said Chief Executive Officer John Valliant, Ph.D. 